Aug. 13 at 3:44 PM
$CMND
Clearmind is advancing its CMND-100 Phase I/II study after its DSMB unanimously approved progression into Parts B and C.
-Part A met its primary safety endpoint in healthy participants
-Part B: two sequential AUD-patient cohorts of six at 80 mg and 160 mg
-Part C: 160 mg daily for five days in a double-blind, placebo-controlled healthy-volunteer study
-Trial sites include Johns Hopkins, Yale, Tel Aviv Sourasky and Hadassah.
#CMND #Biotech #AUD #ClinicalTrials
